钠-葡萄糖共转运体2型抑制剂与心律失常的关系及进展  

The relationship and research progress of sodium glucose cotransporter 2 inhibitors and arrhythmia

作　　者：吴金春 刘韬[1] 黄从新[1] WU Jinchun;LIU Tao;HUANG Congxin(Department of Cardiology,Renmin Hospital of Wuhan University,Cardiovascular Research Institute,Wuhan University,Hubei Key Laboratory of Cardiology,Wuhan,430060,China)

机构地区：[1]武汉大学人民医院心内科,武汉大学心血管病研究所,心血管病湖北省重点实验室,武汉430060

出　　处：《临床心血管病杂志》2022年第8期675-679,共5页Journal of Clinical Cardiology

基　　金：湖北省技术创新专项重大项目(No:2016ACA153);青海省科技厅应用基础研究项目(2022-ZJ-758)。

摘　　要：钠-葡萄糖共转运体2型抑制剂(SGLT2i)是一种具有较好的心血管及肾脏保护作用的新型口服降糖药,相关基础及临床研究报道SGLT2i也具有较好的抗心律失常作用,然而其具体机制尚不明确,目前亦无SGLT2i抗心律失常作用的直接研究证据报告,其中关于SGLT2i对NHE1活性和Na+平衡的报道尚不一致。本文复习归纳国内外关于SGLT2i抑制心律失常的相关文献报道,结合最新研究证据,就SGLT2i与抑制心律失常相关的临床证据、实验研究以及可能的机制等作一综述。Sodium-glucose cotransporter 2 inhibitor(SGLT2i)is a novel type of oral hypoglycemic agent with cardiovascular and renal protection.SGLT2i has also been found to have anti-arrhythmic properties in basic and clinical research.However,the mechanism behind this action is unknown,no direct research evidence demonstrating the anti-arrhythmic effect of SGLT2i has been discovered,and reports on NHE1 activity and salt balance impact of SGLT2i are still conflicting.This paper assesses both the domestic and foreign literature and review the research progress of SGLT2 and cardiac arrhythmia prevention.

关 键 词：钠-葡萄糖共转运体2型抑制剂 心律失常 心房颤动 室性心律失常 

分 类 号：R541.7[医药卫生—心血管疾病]